바이킹 테라퓨틱스(Viking Therapeutics, Inc.)
GB ˙ LSE ˙ US92686J1060
US$29.87 ↑0.55 (1.88%)
2026-06-04
주가
SecurityGB:0VQA / Viking Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership112,339 shares
Latest Disclosed Value $ 3,655,511
Invesco Ltd. reports 4.83% increase in ownership of 0VQA / Viking Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 112,339 shares of Viking Therapeutics, Inc. (GB:0VQA) valued at $3,662,251 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 107,167 shares of Viking Therapeutics, Inc.. This represents a change in shares of 4.83% during the quarter. The current value of the position is $3,355,566 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 112,339 5,172 4.83 3,656 -3.05 0.0006
2026-02-19 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 107,167 -2,130 -1.95 3,770 31.27 0.0006
2025-11-13 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 109,297 13,343 13.91 2,872 12.98 0.0005
2025-08-13 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 95,954 10,973 12.91 2,543 23.88 0.0004
2025-05-12 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 84,981 -787,865 -90.26 2,052 -94.16 0.0004
2025-02-13 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 872,846 -3,376 -0.39 35,123 -36.68 0.0065
2024-11-12 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 876,222 168,343 23.78 55,474 47.83 0.0107
2024-08-13 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 707,879 11,945 1.72 37,525 -34.24 0.0079
2024-05-14 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 695,934 558,371 405.90 57,067 2,129.14 0.0123
2024-02-13 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 137,563 -727,026 -84.09 2,560 -73.25 0.0006
2023-11-13 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 864,589 38,695 4.69 9,571 -28.51 0.0026
2023-08-11 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 825,894 825,894 13,388 0.0035
2023-05-12 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 0 -258,322 -100.00 0 -100.00
2023-02-13 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 258,322 258,322 2,428 0.0007
2022-08-15 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 0 -24,713 -100.00 0 -100.00
2022-05-16 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 24,713 -34,635 -58.36 75 -72.53 0.0000
2022-02-14 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 59,348 -4,451 -6.98 273 -31.92 0.0001
2021-11-15 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 63,799 4,886 8.29 401 13.60 0.0001
2021-08-17 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 58,913 -127,225 -68.35 353 -70.03 0.0001
2021-05-17 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 186,138 16,996 10.05 1,178 23.61 0.0003
2021-02-16 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 169,142 25,856 18.05 953 14.27 0.0003
2020-11-16 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 143,286 940 0.66 834 -18.71 0.0003
2020-08-14 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 142,346 -33,581 -19.09 1,026 24.67 0.0004
2020-05-15 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 175,927 37,879 27.44 823 -25.65 0.0003
2020-02-14 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 138,048 -21,062 -13.24 1,107 1.10 0.0003
2019-11-14 2019-09-30 13F VIKING THERAPEUTICS COM 92686J106 159,110 28,081 21.43 1,095 0.64 0.0003
2019-08-14 2019-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 131,029 16,573 14.48 1,088 -4.39 0.0003
2019-08-14 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 131,029 16,573 1,088
2019-05-15 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 114,456 -15,681 -12.05 1,138 14.26 0.0004
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 130,137 114,923 755.38 996 275.85 0.0004
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 15,214 -447 -2.85 265 77.85 0.0001
2018-08-14 2018-06-30 13F VIKING THERAPEUTICS COM 92686J106 15,661 15,661 149 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.